Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.

Perales IJ, San Agustin K, DeAngelo J, Campbell AM

Open source

DOI
10.1177/1060028019886092
Published
2020 Apr
Container
The Annals of pharmacotherapy
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/1060028019886092,
  title = {Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.},
  author = {Perales IJ and San Agustin K and DeAngelo J and Campbell AM},
  year = {2020},
  journal = {The Annals of pharmacotherapy},
  doi = {10.1177/1060028019886092},
  url = {https://doi.org/10.1177/1060028019886092}
}

RIS

TY  - JOUR
TI  - Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
AU  - Perales IJ
AU  - San Agustin K
AU  - DeAngelo J
AU  - Campbell AM
PY  - 2020
JO  - The Annals of pharmacotherapy
DO  - 10.1177/1060028019886092
UR  - https://doi.org/10.1177/1060028019886092
ER  - 

APA

IJ, P., K, S. A., J, D., & AM, C. (2020). Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.. The Annals of pharmacotherapy. https://doi.org/10.1177/1060028019886092

Source records